Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has established an Audit Committee to enhance its corporate governance structure and improve the decision-making process of its board of directors. The committee is tasked with overseeing the coordination between internal and external auditors, risk management, and internal control, reporting directly to the board. This move is expected to strengthen the company’s governance and compliance with the Hong Kong Listing Rules, thereby potentially improving its industry positioning and stakeholder confidence.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates in the biopharmaceutical industry, focusing on the development and production of biopharmaceutical products. The company is involved in the coordination between internal and external auditors and emphasizes risk management and internal control.
Average Trading Volume: 703,281
Technical Sentiment Signal: Buy
Current Market Cap: HK$71.59B
For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.